Position
Post-doctoral IRTA Fellow,
Medicinal Chemistry Section
Post-doctoral IRTA Fellow,
Computational Chemistry and Molecular Biophysics Section
Education
Ph.D. – Biochemistry (Medicinal Chemistry) – University of Notre Dame
M.Sc. – Biomedical Sciences (Integrative Physiology and Pharmacology) – Wake Forest School of Medicine
B.S. – Chemistry – Wake Forest University
Research Interests
Bradley Keegan received his B.S. in Chemistry from Wake Forest University in 2013 and his M.Sc. from Wake Forest School of Medicine in 2015. His thesis research at Wake Forest involved evaluating baclofen, phenmetrazine, and other pharmacotherapies to treat drug abuse, addiction, and other neuropsychological disorders with the Center for the Neurobiology of Addiction Treatment under the direction of Dr. Allyn Howlett. In 2015 Brad co-founded and served as the Chief Scientific Officer of EncepHeal Therapeutics where he worked to advance modafinil analogs for the treatment of cocaine and methamphetamine addiction. He completed his Ph.D. at the University of Notre Dame in 2022 under the mentorship of Dr. Brian Blagg, and his doctoral thesis research involved the synthesis and evaluation of small molecules to block tau aggregation in Parkinson’s and Alzheimer’s diseases. Brad received a joint IRTA post-doctoral appointment between Dr. Amy Newman’s and Dr. Lei Shi’s labs in the Molecular Targets and Medications Discovery Branch at NIDA where he is currently working toward the design and evaluation of new compounds that target the dopaminergic system for the treatment of substance use disorders.
